NO20055181L - Krystall av benzimidazolderivat og fremgangsmate for fremstilling av samme - Google Patents

Krystall av benzimidazolderivat og fremgangsmate for fremstilling av samme

Info

Publication number
NO20055181L
NO20055181L NO20055181A NO20055181A NO20055181L NO 20055181 L NO20055181 L NO 20055181L NO 20055181 A NO20055181 A NO 20055181A NO 20055181 A NO20055181 A NO 20055181A NO 20055181 L NO20055181 L NO 20055181L
Authority
NO
Norway
Prior art keywords
preparing
crystal
same
benzimidazole derivative
benzimidazole
Prior art date
Application number
NO20055181A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055181D0 (no
Inventor
Naoki Tsuchiya
Mitsuru Teramoto
Hiroshi Saiton
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33447189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055181(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of NO20055181D0 publication Critical patent/NO20055181D0/no
Publication of NO20055181L publication Critical patent/NO20055181L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20055181A 2003-05-14 2005-11-03 Krystall av benzimidazolderivat og fremgangsmate for fremstilling av samme NO20055181L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003135567 2003-05-14
PCT/JP2004/006887 WO2004101551A1 (ja) 2003-05-14 2004-05-14 ベンズイミダゾール誘導体の結晶及びその製造方法

Publications (2)

Publication Number Publication Date
NO20055181D0 NO20055181D0 (no) 2005-11-03
NO20055181L true NO20055181L (no) 2006-01-24

Family

ID=33447189

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055181A NO20055181L (no) 2003-05-14 2005-11-03 Krystall av benzimidazolderivat og fremgangsmate for fremstilling av samme

Country Status (25)

Country Link
US (1) US7649008B2 (es)
EP (1) EP1626048A4 (es)
JP (1) JPWO2004101551A1 (es)
KR (1) KR20060011997A (es)
CN (1) CN1788007A (es)
AR (1) AR044340A1 (es)
AU (1) AU2004238708A1 (es)
BR (1) BRPI0410266A (es)
CA (1) CA2523978A1 (es)
CL (1) CL2004001034A1 (es)
CO (1) CO5660259A2 (es)
EC (1) ECSP056162A (es)
IS (1) IS8177A (es)
MA (1) MA27805A1 (es)
MX (1) MXPA05011851A (es)
NO (1) NO20055181L (es)
NZ (1) NZ542978A (es)
PE (1) PE20050203A1 (es)
RU (1) RU2332417C2 (es)
SA (1) SA04250117B1 (es)
TN (1) TNSN05288A1 (es)
TW (1) TW200505911A (es)
UA (1) UA81493C2 (es)
WO (1) WO2004101551A1 (es)
ZA (1) ZA200508640B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
AU2004266536A1 (en) * 2003-08-22 2005-03-03 Teijin Pharma Limited Drug containing chymase inhibitor as the active ingredient
US20080015240A1 (en) * 2004-11-12 2008-01-17 Mitsuru Teramoto Acid Salt of Benzimidazole Derivative and Crystal Thereof
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法
JP2024521412A (ja) * 2021-06-11 2024-05-31 ジェンザイム・コーポレーション トレブルチニブの結晶形並びにその製造方法及び使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237608B1 (de) 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
JP3668494B2 (ja) 1994-05-31 2005-07-06 帝人株式会社 ナフタレン誘導体
ES2150353B1 (es) 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
HUP0103256A3 (en) 1998-07-15 2002-05-28 Teijin Ltd Thiobenzimidazole derivatives and pharmaceutical compositions containing the compounds
US20040010004A1 (en) * 2000-01-17 2004-01-15 Naoki Tsuchiya Benzimidazole derivatives
PT1249450E (pt) * 2000-01-17 2008-01-02 Teijin Pharma Ltd Derivados de benzimidazole como inibidores de quimase humana
NZ522150A (en) * 2001-02-22 2006-03-31 Teijin Ltd Benzo[b]thiophene derivatives and processes for preparing the same
ATE404551T1 (de) * 2001-05-07 2008-08-15 Teijin Pharma Ltd 3-hydroxymethylbenzo b thiophen-derivate und verfahren zu deren herstellung
KR100902799B1 (ko) 2001-08-24 2009-06-12 데이진 가부시키가이샤 키마제 저해제 및 ａｃｅ 저해제를 유효성분으로 함유하는약제
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r

Also Published As

Publication number Publication date
TW200505911A (en) 2005-02-16
NO20055181D0 (no) 2005-11-03
BRPI0410266A (pt) 2006-05-16
WO2004101551A1 (ja) 2004-11-25
JPWO2004101551A1 (ja) 2006-07-13
KR20060011997A (ko) 2006-02-06
MA27805A1 (fr) 2006-03-01
US7649008B2 (en) 2010-01-19
CL2004001034A1 (es) 2005-03-28
PE20050203A1 (es) 2005-03-26
ECSP056162A (es) 2006-04-19
CN1788007A (zh) 2006-06-14
MXPA05011851A (es) 2006-02-17
IS8177A (is) 2005-12-13
RU2005138868A (ru) 2006-07-10
NZ542978A (en) 2009-04-30
AR044340A1 (es) 2005-09-07
EP1626048A4 (en) 2008-11-12
SA04250117B1 (ar) 2009-09-02
EP1626048A1 (en) 2006-02-15
CO5660259A2 (es) 2006-07-31
ZA200508640B (en) 2007-02-28
UA81493C2 (en) 2008-01-10
AU2004238708A1 (en) 2004-11-25
RU2332417C2 (ru) 2008-08-27
TNSN05288A1 (en) 2007-07-10
US20060293375A1 (en) 2006-12-28
CA2523978A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
AR069530A1 (es) Procedimiento para la fabricacion de un derivado de indolinona
NO20054201L (no) Fremgangsmate for a framstille N-heteroaryl-N-aminoer ved a reagere en N-aryl-karbaminsyrerester med et halo-heteroaryl og analoge prosesser
CY1111295T1 (el) Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2
NO20061396L (no) Nye heterocykliske forbindelser som HSP90-inhibitorer
NO20081101L (no) Regioselektiv metode for fremstilling av benzimidazol-tiofener
NO20070368L (no) Virale polymeraseinhibitorer
NO20053546D0 (no) Triazolderivater som inhibitorer av 11-beta-hydroksysteroiddehydrogenase-1.
NO20071707L (no) Fremstilling av 4,5-dihydro-pyrazolo[3,4-C]Pyrid-2-oner
NO20074388L (no) PGD2 reseptor antagonister for behandling av inflammatoriske sykdommer
DK1511732T3 (da) Fremgangsmåde til fremstilling af quinolinderivater
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
DK1560819T3 (da) Krystallinske cannabinoidderivater og fremgangsmåde til cannabinoidrensning
ATE347550T1 (de) Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure
NO20071012L (no) Fremgangsmate for fremstilling av D-erytro-2,2-difluor-2-deoksy-1-oksoribosederivat
DE60318142D1 (de) Verstärker für breitbandige optische Ramanverstärkung
NO20083068L (no) Optisk aktive karbamater, fremgangsmate for deres fremstilling og anvendelse derav som farmasoytiske mellomprodukter
EA200600485A1 (ru) Способ получения производных 2-оксо-1-пирролидина
DK1403265T3 (da) Industriel fremgangsmåde til fremstilling af 5-bis(carboxymethyl)amino-3-carboxymethyl-4-cyano-2-thiophencarboxylsyretetraestre og anvendelse heraf til syntese af divalente ranelsyresalte og hyddrater heraf
DK1513800T3 (da) Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
NO20071634L (no) Effektiv syntese av 4,5-dihydro-pyrazolo(3,4-C)pyrid-2-oner
NO20071325L (no) Fremgangsmate for fremstilling av hemicellulose fra lignocellulosemateriale
NO20053473D0 (no) Fremgangsmate for fremstilling av R,R (eller S,S) konfigurasjonen av glykopyrroniumstereoisomerer
TW200505911A (en) Crystal of benzimidazole derivative and process for producing the same
MY138550A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
DE602005013499D1 (de) Sterilisationsanlage und verfahren zum vergrössern der kapazität für eine sterilisationsanlage

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application